Shanghai Junshi Biosciences Co (SHSE:688180) Net Income (Continuing Operations) : ¥-1,382 Mil (TTM As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Shanghai Junshi Biosciences Co Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Shanghai Junshi Biosciences Co's Net Income (Continuing Operations) for the three months ended in Dec. 2024 was ¥-393 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Dec. 2024 was ¥-1,382 Mil.

Shanghai Junshi Biosciences Co Net Income (Continuing Operations) Historical Data

The historical data trend for Shanghai Junshi Biosciences Co's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Junshi Biosciences Co Net Income (Continuing Operations) Chart

Shanghai Junshi Biosciences Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Net Income (Continuing Operations)

Get a 7-Day Free Trial

-1,665.64

-728.18

-2,582.10

-2,533.88

-1,381.58

Shanghai Junshi Biosciences Co Quarterly Data
	Dec16	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Net Income (Continuing Operations)	Get a 7-Day Free Trial															-978.75	-299.65	-388.80	-300.28	-392.85

Shanghai Junshi Biosciences Co Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-1,382 Mil.

Shanghai Junshi Biosciences Co (SHSE:688180) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Shanghai Junshi Biosciences Co Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of Shanghai Junshi Biosciences Co's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.

Shanghai Junshi Biosciences Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Junshi Biosciences Co Ltd (SHSE:688180) » Definitions » Net Income (Continuing Operations)

Comparable Companies

Traded in Other Exchanges

01877:Hong Kong 8SJ:Germany

Address

No. 987 Cai Lun Road, Level 4, Pilot Free Trade Zone, Shanghai, CHN

Website

https://www.junshipharma.com

Shanghai Junshi Biosciences Co Ltd is mainly engaged in innovation-driven biopharmaceutical business. The company's main products include teriprizumab injection, Etesevimab, adalimumab injection, and other drugs, which are used to treat malignant tumors, autoimmune system diseases, chronic metabolic diseases, nervous system diseases, and infectious diseases. The group's operations are mainly located in the PRC and the United States of America.

Executives

	Directors, senior managers
Chen Ying Ge	senior management
Xiong Jun	Director
Yin Kan	senior management
Xie Wan	senior management

Shanghai Junshi Biosciences Co Headlines

No Headlines